Literature DB >> 34327570

Increased interleukin-17A-producing γδT cells predict favorable survival in elderly patients with LUAD and LUSC.

Kele Cui1,2,3, Xinyu Mei4, Min Cheng5,6,7.   

Abstract

PURPOSE: Aging is closely related to the occurrence of many diseases, including cancer, and involves changes in the immune microenvironment. γδT cells are important components of resident lymphocytes in mucosal tissues. However, little is known about the effects that the aged lung has on γδT cells and their prognostic significance in non-small cell lung cancer.
METHODS: In the current study, the expression of γδTCR and IL-17A was measured by immunohistochemistry in paraffin-embedded lung tissues from 168 patients with adenocarcinoma (LUAD) and 144 patients with squamous cell carcinoma (LUSC). Furthermore, gene transcription patterns in LUAD and LUSC tumors and normal controls were extracted from TCGA and GTEx databases and were analyzed.
RESULTS: High frequency of γδT cells was observed in patients with LUAD and LUSC, whereas the levels of CD4 + T cells, CD8 + T cells and CD56 + cells were decreased. Elevated γδT cells in tumors were mainly IL-17A-releasing γδT17 cells, which were found to be enriched in aged patients. High γδT cell levels positively corelated with the overall survival (OS) of patients, especially the 5-year OS in the elderly. Further analysis of gene transcription patterns indicated that increased expression of LTBR, HES1, RORC, CCR6, IL1, and IL23A may contribute to the transformation of the tumor microenvironment in a manner conducive to γδT17 cell development and differentiation. Finally, gene analysis between different age groups revealed that the expression of CCR6 and IL7 in LUAD, as well as Hes1, IL7, and IL23A in LUSC, were remarkably higher in elderly (age ≥ 60 years) than in younger individuals (age < 60 years).
CONCLUSION: Our findings suggest that intrinsic alterations in the aging lung lead to γδT17 cell enrichment, which subsequently may exert anti-tumor effects in the elderly.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Elderly; LUAD; LUSC; Overall survival; γδT cells

Year:  2021        PMID: 34327570     DOI: 10.1007/s00432-021-03742-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yu-Mu Chen; Chien-Hao Lai; Kun-Ming Rau; Cheng-Hua Huang; Huang-Chih Chang; Tung-Ying Chao; Chia-Cheng Tseng; Wen-Feng Fang; Yung-Che Chen; Yu-Hsiu Chung; Yi-Hsi Wang; Mao-Chang Su; Kuo-Tung Huang; Shih-Feng Liu; Hung-Chen Chen; Ya-Chun Chang; Yu-Ping Chang; Chin-Chou Wang; Meng-Chih Lin
Journal:  Lung Cancer       Date:  2016-05-31       Impact factor: 5.705

Review 2.  Lung-resident γδ T cells and their roles in lung diseases.

Authors:  Min Cheng; Shilian Hu
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

Review 3.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention.

Authors:  Brett C Bade; Charles S Dela Cruz
Journal:  Clin Chest Med       Date:  2020-03       Impact factor: 2.878

4.  Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients.

Authors:  Xi Chen; Jin Wan; Jiankun Liu; Wei Xie; Xinwei Diao; Jianping Xu; Bo Zhu; Zhengtang Chen
Journal:  Lung Cancer       Date:  2010-09       Impact factor: 5.705

5.  Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells.

Authors:  Jinyou Duan; Hachung Chung; Erin Troy; Dennis L Kasper
Journal:  Cell Host Microbe       Date:  2010-02-18       Impact factor: 21.023

Review 6.  The natural and the inducible: interleukin (IL)-17-producing γδ T cells.

Authors:  Yueh-hsiu Chien; Xun Zeng; Immo Prinz
Journal:  Trends Immunol       Date:  2012-12-22       Impact factor: 16.687

7.  Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism.

Authors:  Min Cheng; Liting Qian; Guodong Shen; Geng Bian; Tingjuan Xu; Weiping Xu; Gan Shen; Shilian Hu
Journal:  Cancer Res       Date:  2014-06-19       Impact factor: 12.701

8.  Lung cancer in young adults.

Authors:  W Bourke; D Milstein; R Giura; M Donghi; M Luisetti; A H Rubin; L J Smith
Journal:  Chest       Date:  1992-12       Impact factor: 9.410

Review 9.  Aging, immune senescence, and immunotherapy: A comprehensive review.

Authors:  Rawad Elias; Kevan Hartshorn; Osama Rahma; Nina Lin; Jennifer E Snyder-Cappione
Journal:  Semin Oncol       Date:  2018-10-24       Impact factor: 5.385

10.  Molecular signature for senile and complicated cataracts derived from analysis of sumoylation enzymes and their substrates in human cataract lenses.

Authors:  Fang-Yuan Liu; Jia-Ling Fu; Ling Wang; Qian Nie; Zhongwen Luo; Min Hou; Yuan Yang; Xiao-Dong Gong; Yan Wang; Yuan Xiao; Jiawen Xiang; Xuebin Hu; Lan Zhang; Mingxing Wu; Weirong Chen; Bing Cheng; Lixia Luo; Xinyu Zhang; Xialin Liu; Danying Zheng; Shengsong Huang; Yizhi Liu; David Wan-Cheng Li
Journal:  Aging Cell       Date:  2020-08-22       Impact factor: 9.304

View more
  3 in total

1.  A Pyroptosis-Related Signature Predicts Overall Survival and Immunotherapy Responses in Lung Adenocarcinoma.

Authors:  Kaibin Zhu; An Yan; Fucheng Zhou; Su Zhao; Jinfeng Ning; Lei Yao; Desi Shang; Lantao Chen
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

Review 2.  Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy.

Authors:  Yuan Song; Yonghao Liu; Huey Yee Teo; Haiyan Liu
Journal:  Front Immunol       Date:  2022-06-07       Impact factor: 8.786

3.  Distribution and Clinical Significance of IL-17A in Tumor-Infiltrating Lymphocytes of Non-Small Cell Lung Cancer Patients.

Authors:  Rui Xu; Xing Ke; Wenwen Shang; Shuna Liu; Xin Fu; Ting Wang; Shuxian Jin
Journal:  Pathol Oncol Res       Date:  2022-05-18       Impact factor: 2.874

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.